Breaking News

Phoenix Molecular, WuXi STA Reach Drug Supply Milestone

Completes clinical trial supply to support Phase I/Ib study of PMD-026 for TNBC

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Phoenix Molecular Designs (PhoenixMD), a biotechnology company designing cancer therapeutics targeting essential kinases, has completed the clinical trial supply manufacture for PMD-026. PhoenixMD’s lead program, PMD-026, is the first RSK inhibitor for the treatment of triple-negative breast cancer (TNBC). The clinical trial supply was undertaken by STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and is being used to support IND-enabling toxicology studies and an upcoming Ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters